ABEONA THERAPEUTICS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ABEONA THERAPEUTICS INC. (ABEO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $112.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-18.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2024-03-18
- ABEONA THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $112.00K.
- ABEONA THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was -$1.20M, a 122.71% decline from fiscal 2021.
- ABEONA THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was $5.30M, a 6.56% decline from fiscal 2020.
- ABEONA THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $5.67M, a 12784.09% increase from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2023-12-31 | $112.00K 10-K · filed 2024-03-18 | |
| 2022-12-31 | -$1.20M 10-K · filed 2024-03-18 | |
| 2021-12-31 | $5.30M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $5.67M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $44.00K 10-K · filed 2021-03-24 | |
| 2018-12-31 | $24.00K 10-K · filed 2020-03-16 | |
| 2017-12-31 | $46.00K 10-K · filed 2020-03-16 | |
| 2016-12-31 | $14.00K 10-K · filed 2019-03-18 | |
| 2014-12-31 | $7.85M 10-K · filed 2015-03-31 | |
| 2013-12-31 | -$1.74M 10-K · filed 2015-03-31 | -$1.74M 10-K · filed 2014-03-26 |
| 2012-12-31 | $787.00K 10-K · filed 2014-03-26 | $682.00K 10-K · filed 2013-03-20 |
| 2011-12-31 | $4.00K 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |